Last reviewed 2026-06-02 · How we verify

Dactiran (PIPERIDOLATE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Dactiran (generic name: PIPERIDOLATE) is a piperidolate drug. It is currently in Phase 2 development.

Unfortunately, the mechanism of action of Dactiran is not well understood.

Dactiran is a small molecule with the synonyms 1087-A.N., JB-305, PIPERIDOLATE, PIPERIDOLATE, and PIPERIDOLATO.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PIPERIDOLATE
Drug class	piperidolate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In simple terms, a drug's mechanism of action refers to how it works at a molecular level to produce its effects. For Dactiran, this process is not well described, making it difficult to explain how it might interact with the body. More research is needed to uncover the details of its mechanism.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dactiran CI brief — competitive landscape report
Dactiran updates RSS · CI watch RSS

Frequently asked questions about Dactiran

What is Dactiran?

Dactiran (PIPERIDOLATE) is a piperidolate drug.

How does Dactiran work?

Unfortunately, the mechanism of action of Dactiran is not well understood.

What is the generic name of Dactiran?

PIPERIDOLATE is the generic (nonproprietary) name of Dactiran.

What drug class is Dactiran in?

Dactiran belongs to the piperidolate class. See all piperidolate drugs at /class/piperidolate.

What development phase is Dactiran in?

Dactiran is in Phase 2.

Drug class: All piperidolate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing